Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;2014:140063.
doi: 10.1530/EDM-14-0063. Epub 2014 Sep 1.

Effect of Astragalus Membranaceus Extract on Diabetic Nephropathy

Free PMC article

Effect of Astragalus Membranaceus Extract on Diabetic Nephropathy

Jiman Kim et al. Endocrinol Diabetes Metab Case Rep. .
Free PMC article


Diabetic nephropathy, a microvascular complication of diabetes, is a progressive kidney disease caused by angiopathy of the capillaries in the kidney glomeruli. Herein, we report a case of a 62-year-old patient with a 30 year history of diabetes, who showed a substantial improvement in diabetic nephropathy on administration of 30 g of Astragalus membranaceus extract per day. After 1 month, estimated glomerular filtration rate increased from 47 to 72 ml/min per 1.73 m(2) and was subsequently maintained at the 1-month follow-up. Urinary protein levels also decreased following treatment. Herein, we present and discuss the evidence and mechanism of A. membranaceus on diabetic nephropathy in this patient.

Learning points: Diabetic nephropathy is a progressive kidney disease.Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are currently used to prevent and delay the progression of diabetic nephropathy. However, their effects are not sufficient to prevent a decline in kidney function.Furthermore, combination therapy with an ACE inhibitor and an ARB can produce adverse effects without additional benefits.In the early phase of diabetic nephropathy, administration of Astragalus membranaceus can be a therapeutic option.


Figure 1
Figure 1
Changes in estimated glomerular filtration rate (eGFR). 0 week: April 7, 2014; 4 weeks: May 3, 2014; 8 weeks: June 7, 2014.
Figure 2
Figure 2
Changes in urinary protein. X axis, time in weeks; Y axis, urinary protein (mg/dl); 0 week, April 7, 2014; 4 weeks, May 3, 2014; 8 weeks, June 7, 2014.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles


    1. Wang SL, Head J, Stevens L & Fuller JH. 1996Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care 19305–312 10.2337/diacare.19.4.305 - DOI - PubMed
    1. American Diabetes Association Standards of medical care in diabetes – 2013. Diabetes Care 36Suppl 12013S11–S66 10.2337/dc13-S004 - DOI - PMC - PubMed
    1. Vivian E & Mannebach C. 2013Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?. Drugs in Context 2013212249.10.7573/dic.212249 - DOI - PMC - PubMed
    1. Li M, Wang W, Xue J, Gu Y & Lin S. 2011Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy. Journal of Ethnopharmacology 133412–419 10.1016/j.jep.2010.10.012 - DOI - PubMed
    1. Zhang J, Xie X, Li C & Fu P. 2009Systematic review of the renal protective effect of Astragalus membranaceus (root) on diabetic nephropathy in animal models. Journal of Ethnopharmacology 126189–196 10.1016/j.jep.2009.08.046 - DOI - PubMed